ALK+ large B-cell lymphoma

From Wikipedia, the free encyclopedia

ALK+ large B-cell lymphoma is a type of lymphoma.[1][2]:378 It was first reported in 1997.[2]:378[3][4] It is a rare, aggressive large B-cell process that shows ALK expression.[2]:378[3][5] It is distinct from anaplastic large cell lymphoma, a T-cell lymphoma.[2]:564[3][6]

Pathophysiology

Upregulation of ALK is mainly due to chromosomal translocation t(2;17), resulting in a fusion gene of CLTC with ALK,[4][7] but can rarely be due to t(2;5), fusing NPM1 with ALK;[2]:378 the later is the usual finding in anaplastic large cell lymphoma (ALCL).[4][7] The t(2;17) translocation occurs in less than 1% of cases of ALK+ ALCL, but has been identified in inflammatory myofibroblastic tumors.[3]

There is no association with Epstein–Barr virus[2]:378[6] or HHV8,[6] or immunosuppression.[2]:378 The cells are CD20 and CD30 negative,[8]:306 showing weak focal expression in 3% and 6% respectively.[2]:378 They are EMA and CD138 positive,[8]:306 showing 100% expression respectively.[2]:378

Diagnosis

The median age of diagnosis is approximately late thirties to early forties.[2]:378[3][5] The estimates of childhood disease vary (8%,[9] 15%,[3] 30%[2]:378) but it can be seen at any age.[5][8]:306

The disease usually arises in lymph nodes, particularly the neck, but extranodal involvement, including in the gastrointestinal tract, nasal cavity, ovary and brain, has been described.[3][5] Morphologically, there are large immunoblast-like cells with large central nucleoli, often cellular clusters, with a predilection for the lymph node sinuses[2]:378[4][8]:306 in a cohesive pattern that can suggest carcinoma cells.[2]:378[8]:306

Treatment

See also

References

Related Articles

Wikiwand AI